Medicare’s drug price negotiation program has expanded again, with federal officials announcing agreements on 15 additional medicines and, for the first time, a treatment covered under Part B. The move deepens the government’s direct role in determining what older Americans and people with disabilities pay for some of the costliest therapies in the country.
The new batch of negotiated products will not see lower prices at the pharmacy counter immediately, but it underscores that the Inflation Reduction Act’s drug provisions are shifting from legal theory to practical reality for patients, manufacturers, and investors.
How the latest Medicare negotiation round reshapes the program
The Centers for Medicare & Medicaid Services has now reached pricing agreements with manufacturers on 15 more drugs that account for significant spending in both Part D and, for the first time, Part B. Earlier negotiation rounds focused on outpatient prescription medicines. By adding a Part B product, which is typically administered in a doctor’s office or hospital clinic, Medicare is extending its new bargaining power into services billed directly by clinicians.
According to federal officials, the selected medicines rank among the highest in total Medicare spending, with some generating billions in annual outlays before rebates. The list includes treatments for conditions such as diabetes, heart disease, autoimmune disorders, and cancer, all of which drive large portions of Medicare’s drug budget. The government’s authority to negotiate prices for these products stems from the Inflation Reduction Act, which created a staged process that begins with identification of high-spend drugs, moves through confidential discussions with manufacturers, and ends in a “maximum fair price” that will apply to Medicare coverage.
Earlier this year, the first negotiated prices were announced for an initial group of drugs that will see new Medicare payment levels start in 2026. The latest 15 medicines are slated to follow on a similar timeline, with the agreed prices scheduled to take effect starting in 2027. Federal officials have described this expansion as a planned next phase rather than a one-off concession, pointing to a multi-year schedule that gradually brings more products into the negotiation program.
Drugmakers initially challenged the policy in court, arguing that the negotiation framework amounted to unconstitutional government price controls. Judges rejected several of those claims, and manufacturers that had previously signaled resistance have now entered into agreements on the new set of medicines. The shift from litigation to participation reflects a recognition that the program is moving forward and that companies must now navigate its rules rather than simply oppose them.
Why the new negotiated drugs and first Part B product matter for patients and markets
For Medicare beneficiaries, the practical impact will arrive when the new prices begin to apply in 2027. The negotiated discounts are expected to lower what the program pays for each selected drug, which in turn can reduce premiums and out-of-pocket costs for people enrolled in Part D plans. In some cases, beneficiaries who rely on high-cost therapies could see their annual spending fall by hundreds or thousands of dollars once the new rates are in place, especially when combined with the Inflation Reduction Act’s cap on yearly Part D out-of-pocket expenses.
The inclusion of a Part B medicine is a particularly significant shift. Part B drugs are often used for complex conditions such as cancer or autoimmune disease and can carry price tags of tens of thousands of dollars per course of treatment. Because Part B cost sharing is typically a percentage of the drug’s price, any reduction in Medicare’s payment can directly lower the coinsurance that patients owe. By targeting one of these products for negotiation, Medicare is testing whether the same model that applied to pharmacy-dispensed drugs can also work in the clinic setting, where physicians, hospitals, and infusion centers are central players.
Manufacturers, for their part, now face a more concrete sense of how negotiation will affect revenue. The agreed discounts for the first wave of drugs already produced estimated savings for the federal government that run into the billions of dollars over a decade, and the new 15 medicines will add to that total. Investors are watching closely to see how much of that reduction comes directly out of company margins and how much is offset by volume growth or portfolio shifts toward products that are not yet eligible for negotiation.
The policy also has implications for research and development strategy. Some drugmakers have warned that lower Medicare prices could lead them to scale back investment in certain therapeutic areas or to delay launches for older patients. Others argue that the law’s timelines, which exempt newer products for several years, still leave room for strong returns on innovative treatments. Analysts expect firms to pay closer attention to how quickly their drugs reach the spending thresholds that put them in line for future negotiation cycles.
Health policy experts have noted that the latest agreements build on earlier steps such as the cap on insulin copays and limits on annual out-of-pocket spending in Part D. Together, these measures are reshaping how Medicare shares drug costs among taxpayers, plans, manufacturers, and patients, and they are likely to influence private insurers that benchmark their coverage to Medicare standards.
